Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
2,654,611
-
Share change
-
-74,691
-
Total reported value
-
$14,778,000
-
Price per share
-
$5.57
-
Number of holders
-
19
-
Value change
-
-$1,301,577
-
Number of buys
-
11
-
Number of sells
-
7
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q1 2018
As of 31 Mar 2018,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,654,611 shares.
The largest 10 holders included
683 Capital Management, LLC, MEITAV DASH INVESTMENTS LTD, Park West Asset Management LLC, Nantahala Capital Management, LLC, Ibex Investors LLC, MORGAN STANLEY, P.A.W. CAPITAL CORP, RENAISSANCE TECHNOLOGIES LLC, DEUTSCHE BANK AG\, and UBS Group AG.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.